Chemotherapy-induced peripheral neuropathy

NeurExo Sciences and Henry Ford Health System Present Preclinical Data on Exosomes at ISEV2019 Annual Meeting

Retrieved on: 
Friday, April 26, 2019
Medicine, Clinical medicine, Cancer treatments, Chemotherapy, Cancer, Chemotherapy-induced peripheral neuropathy, Exosome, Peripheral neuropathy

Among their key findings, Henry Ford researchers demonstrated the ability of exosomes to suppress chemotherapy-induced peripheral neuropathy and enhance the anti-tumor effects of platinum drugs, which are commonly used to treat cancers.

Key Points: 
  • Among their key findings, Henry Ford researchers demonstrated the ability of exosomes to suppress chemotherapy-induced peripheral neuropathy and enhance the anti-tumor effects of platinum drugs, which are commonly used to treat cancers.
  • Neurotoxicity often requires platinum drug dose reduction, compromising therapeutic efficacy of platinum drugs to suppress tumor progression.
  • Tumor bearing mice treated with platinum drugs along with CEC-exos (n=7/group) exhibited significant reduction of platinum-drug induced peripheral neuropathy.
  • "Our preclinical data demonstrate the ability of the exosome treatment to ameliorate platinum-drug induced peripheral neuropathy," said Dr. Zhang.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insights, 2019 Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 31, 2019
Health, Pharmaceutical, Medicine, Clinical medicine, Cancer, Chemotherapy, Chemotherapy-induced peripheral neuropathy, Oncology, Peripheral neuropathy, Erythropoietin, Drug pipeline

The "Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chemotherapy Induced Peripheral Neuropathy (CIPN) development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline products by developmental stage, product type, molecule type, and administration route.

Global Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market, 2016-2027

Retrieved on: 
Wednesday, December 5, 2018
Medicine, Cancer, Chemotherapy, Chemotherapy-induced peripheral neuropathy, Oncology, Peripheral neuropathy, Taxane

The "Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib.
  • The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report gives the thorough understanding of the CIPN by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
  • The Chemotherapy-Induced Peripheral Neuropathy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries.

Study of the Efficacy of Neurofeedback Training on Chemotherapy-Induced Neuropathy Receives 2018 FNAN Award

Retrieved on: 
Monday, May 21, 2018
Medicine, Clinical medicine, Neuroscience, Electroencephalography, Neurotechnology, Cancer, Chemotherapy, Chemotherapy-induced peripheral neuropathy, Neurofeedback, Peripheral neuropathy, Quantitative electroencephalography

Estimates of this incidence of chemotherapy-induced peripheral neuropathy (CIPN) after treatment can range as high as 71% to 96%.

Key Points: 
  • Estimates of this incidence of chemotherapy-induced peripheral neuropathy (CIPN) after treatment can range as high as 71% to 96%.
  • Each patient in the neurofeedback group received twenty sessions of training based on their own qEEG pattern.
  • This study shows that neurofeedback can offer an alternative to pain medication which is well accepted by patients."
  • FNAN awards its prize for the best neurofeedback article on an annual basis.